REG - e-Therapeutics plc - Last Day of Dealings on AIM

E-TherapeuticsAnnouncement

08/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240508:nRSH4980Na&default-theme=true

RNS Number : 4980N  e-Therapeutics plc  08 May 2024

 

 

e-therapeutics plc

("e-therapeutics" or "ETX" or the "Company")

 

Last Day of Dealings on AIM

 

 

London, UK, 8 May 2024 - e-therapeutics plc (AIM: ETX), a company integrating
computational power and biological data to discover life-transforming RNAi
medicines, provides a further update with regards to the cancellation of
admission of the Company's ordinary shares to trading on AIM (the
"Cancellation"), as originally announced on 10 April 2024 and as approved by
shareholders at the general meeting held on 29 April 2024.

 

Shareholders are reminded that the last day of trading in ETX's ordinary
shares on AIM is today, 8 May 2024. Cancellation will become effective at
7:00a.m. on 9 May 2024.

 

Following Cancellation, shareholders are encouraged to sign up to the
Company's email news alerts via the e-therapeutics website to remain up to
date with the Company's developments as we continue to advance our portfolio
and target opportunities as a private company. The Company will maintain its
shareholder communications email address -
investorrelations@etherapeutics.co.uk - and investors wishing to enter into
dialogue with the Company are encouraged to email that address.

 

Dealing Arrangements

 

The Company's ordinary shares will be admitted to trading on the JP
Jenkins securities matching platform from 9 May 2024.

 

JP Jenkins provides a securities matching venue for unlisted or unquoted
assets in companies, enabling shareholders and prospective investors to buy
and sell shares on a matched bargain basis. JP Jenkins is a trading name of
InfinitX Limited and Appointed Representative of Prosper Capital LLP
(FRN453007).

 

Shareholders wishing to trade these securities can do so through their
stockbroker. Trades will be conducted at a level that JP Jenkins is able to
match a willing seller and a willing buyer. Trades can be conducted, and
limits can be accepted, during normal business hours. Shareholders or
potential investors can place limits via their existing UK regulated
stockbroker.

 

The indicative pricing for the ordinary Shares (ISIN: GB00B2823H99), as well
as the transaction history, will be available on the JP Jenkins website
at (https://jpjenkins.com/company/e-therapeutics-plc/).

 

The provision of the matched bargain facility will be kept under review by the
Board and, in determining whether to continue to offer a matched bargain
facility, the Company shall consider expected (and communicated) shareholder
demand for such a facility as well as the composition of the Company's
register of members and the costs to the Company and shareholders.

 

Following Cancellation, SP Angel Corporate Finance LLP will cease to act as
nominated adviser and corporate broker to the Company.

 

Enquiries

 

 e-therapeutics plc
 Ali Mortazavi,                                                                            Tel: +44 (0) 20 4551 8888
 CEO

                                                                                         www.etherapeutics.co.uk
 Timothy Bretherton, CFO

      SP Angel Corporate Finance LLP                                                       Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 JP Jenkins Limited

 Matched Bargain Facility                                                                  Tel: +44 (0)20 7469 0937

 Veronika Oswald

 

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") uniquely combines computation and RNAi to discover
and develop life-transforming medicines. ETX's proprietary RNAi chemistry
platform, GalOmic™, enables generation of specific, potent, and durable
siRNA therapeutics for effective silencing of novel gene targets in
hepatocytes. The cutting-edge HepNet™ computational platform allows ETX to
discover better medicines faster through generation of novel insights and
increased automation across all stages of drug development. HepNet™
encompasses an extensive hepatocyte-specific knowledgebase and a suite of
advanced AI-driven approaches which enable identification of novel gene
targets, rapid target-indication assessment, and predictive in silico siRNA
design. The Company has specialist expertise and a robust position in applying
computation to biology. Its computational approaches have been extensively
validated through generation of data from pipeline programs and successful
drug discovery collaborations with biopharma companies, such as Novo Nordisk,
Galapagos NV, and iTeos Therapeutics.

 

Leveraging the combined capabilities of HepNet™ and GalOmic™, ETX is
progressing a therapeutic pipeline of highly differentiated RNAi candidates
across a variety of therapeutic areas with high unmet need. The Company has
generated positive proof-of-concept data on preclinical assets in metabolic
dysfunction-associated steatohepatitis (MASH), dry age-related macular
degeneration (dry AMD), haemophilia, and cardiometabolic disease, further
validating its computationally enhanced approach to research and development.
ETX is currently progressing lead assets ETX-312 for MASH and ETX-407 for dry
AMD through IND-enabling studies and towards the clinic.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQDLFBZELZBBD